Meshrkey, Fibi
Scheulin, Kelly M.
Littlejohn, Christopher M.
Stabach, Joshua
Saikia, Bibhuti
Thorat, Vedant
Huang, Yimin
LaFramboise, Thomas
Lesnefsky, Edward J.
Rao, Raj R.
West, Franklin D.
Iyer, Shilpa http://orcid.org/0000-0001-6287-2232
Funding for this research was provided by:
DHHS Office of the Secretary (NIHR15NS080157-01A1, NIHR01LM013067, NIH R21CA248138, 1R01HD110536-01A1)
U.S. Department of Defense (W81XWH-16-1-0181)
Article History
Received: 17 May 2023
Accepted: 25 October 2023
First Online: 7 November 2023
Declarations
:
: The current study was conducted with patient fibroblasts provided by the Medical University of Salzburg (SBG), Austria. Informed consent was obtained to use these samples for research in an anonymized way. In accordance with federal regulations regarding the protection of human research subjects (32 CFR 219.101(b) [CitationRef removed]), the University of Arkansas Office of Research Compliance determined that the project titled “Patient-specific human induced pluripotent stem cells for mitochondrial diseases” was deemed exempt from Institutional Review Board (IRB) oversight and human research subjects’ protection regulations on July 14, 2016.
: Not applicable.
: The authors have declared that no competing interests exist.